The stock prices of vaccine makers Moderna and Pfizer surged Friday along with stay-at-home stocks like Zoom Video and Peloton.

The antiviral drug could put a dent into the uptake of COVID-19 vaccines, as countries still struggle to reach herd immunity due to vaccine hesitancy.

Year-to-date, shares of BioNTech, Moderna, and Pfizer have surged 357%, 275%, and 28%, respectively.

Wall Street analysts appear less keen than retail traders on vaccine makers such as Moderna, after a breakneck rally over the last year.

"To justify $200 billion in value, one has to assume 1 to 1.5 billion doses of COVID-19 vaccine each year from 2022-2038," BofA argued.

"To justify $200 billion in value, one has to assume 1 to 1.5 billion doses of COVID-19 vaccine each year from 2022-2038," BofA argued.

Moderna, the almost 11 year old company that created a 95% effective pandemic ending vaccine in less than a year, is now worth more than Merck.

Alexion Therapeutics, which is set to be acquired by AstraZeneca, will be replaced by Moderna in the market-cap weighted index.

The CDC's guidance to pause the use of J&J's COVID vaccine came following reports of 6 rare blood clots in patients after receiving the single-dose.

Moderna and Johnson & Johnson's vaccines are approved for adults over 18, while the vaccine from Pfizer and BioNTech is approved for individuals over 16.

The company during its earnings call also announced the September departure of Tal Zaks, its chief medical officer.

Moderna slumped as much as 6.2% on Friday as investors sold off on encouraging news regarding the company’s coronavirus vaccine. A panel of Food and Drug Administration experts recommended the vaccine be approved for emergency use on Thursday, a key step that will set the shot up for distribution in […]

Moderna jumped as much as 11% on Monday after the company filed for US FDA approval of its coronavirus vaccine to be widely distributed. Studies conducted on 196 people show the vaccine shot is more than 94% effective at protecting people from becoming ill with the virus. Visit Business Insider’s […]

Strong preliminary data results from Moderna’s COVID-19 vaccine has spurred a selloff in rival vaccine developers Pfizer, BioNTech, and AstraZeneca. Moderna said on Monday that its COVID-19 vaccine candidate demonstrated an efficacy rate of 94.5% in a trial of more than 30,000 patients. Last week, Pfizer and its partner BioNTech […]

Shares in Moderna rose 9% in pre-market trading on Monday after an independent health board said its COVID-19 vaccine is almost 95% effective. Moderna plans to apply for Emergency Use Authorization with the US Food and Drug Administration (FDA) in the coming weeks. Visit Business Insider’s homepage for more stories. […]

Moderna shares jumped as much as 5% in pre-market trading on Thursday after Dr. Anthony Fauci predicted positive data from a second COVID-19 vaccine. The US drugmaker said on Thursday that it now has enough data to begin the first interim analysis of its vaccine, before submitting it to an […]

US stocks rose Wednesday amid investor optimism around further economic stimulus and the prospect of a coronavirus vaccine. The benchmark S&P 500 closed less than 0.2% from a record. It last reached an all-time high on Feb. 19, prior to the coronavirus crash. Shares of Moderna spiked after President Trump […]